Eli Lilly (LLY) Retained Earnings (2009 - 2026)
Eli Lilly (LLY) posted Retained Earnings of $29.5 billion for Q1 2026, up 1124.79% quarter-over-quarter from -$2.9 billion in Q4 2025, and up 881.91% year-on-year from $3.0 billion in Q1 2025.
Eli Lilly (LLY) Retained Earnings (2009 - 2026) Analysis & Trends
Eli Lilly (LLY) has reported Retained Earnings for 18 consecutive years, with $29.5 billion the latest figure, recorded in Q1 2026.
- Retained Earnings for Q1 2026 came in at $29.5 billion, up 881.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $29.5 billion (up 881.91% YoY), and the FY2025 annual result was -$2.9 billion, up 33.36% from the prior year.
- Retained Earnings was $29.5 billion for Q1 2026 at Eli Lilly, up from -$2.9 billion in the prior quarter.
- Over five years, Retained Earnings peaked at $29.5 billion in Q1 2026 and troughed at -$4.4 billion in Q2 2024.
- Average Retained Earnings over 5 years is $2.5 billion, with a median of -$3.8 billion recorded in 2025.
- Year-over-year, Retained Earnings sank 144.28% in 2023 and soared 881.91% in 2026.
- Over 5 years, Retained Earnings stood at $10.0 billion in 2022, then plunged by 143.09% to -$4.3 billion in 2023, then advanced by 0.12% to -$4.3 billion in 2024, then surged by 33.36% to -$2.9 billion in 2025, then surged by 1124.79% to $29.5 billion in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were $29.5 billion in Q1 2026, -$2.9 billion in Q4 2025, and -$3.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 29.51 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -14.83 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -17.87 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 9.67 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 66.72 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -190.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 78.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -7.20 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | -140.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.51 Bn |
| Dec 31, 2025 | -2.88 Bn |
| Sep 30, 2025 | -3.21 Bn |
| Jun 30, 2025 | 17.38 Bn |
| Mar 31, 2025 | -3.77 Bn |
| Dec 31, 2024 | -4.32 Bn |
| Sep 30, 2024 | -4.27 Bn |
| Jun 30, 2024 | -4.38 Bn |
| Mar 31, 2024 | -4.30 Bn |
| Dec 31, 2023 | -4.33 Bn |
| Sep 30, 2023 | -3.78 Bn |
| Jun 30, 2023 | -3.79 Bn |
| Mar 31, 2023 | -3.78 Bn |
| Dec 31, 2022 | 10.04 Bn |
| Sep 30, 2022 | 10.01 Bn |
| Jun 30, 2022 | 8.56 Bn |
| Mar 31, 2022 | 9.37 Bn |
| Dec 31, 2021 | 8.96 Bn |
| Sep 30, 2021 | -6.17 Bn |
| Jun 30, 2021 | -6.29 Bn |